APRE
Aprea Therapeutics Inc
Halal Rating :
Last Price
$3.91
Last updated:
Market Cap
-
7D Change
14.33%
1 Year Change
-32.82%
Company Overview
Industries
Exchange
Next Earnings Date
Aprea Therapeutics Inc is a biopharmaceutical company focused on developing novel cancer therapeutics targeting DNA damage response pathways. The company's lead program is focused on the development and commercialization of ATRN-119, a potentially first-in-class small molecule dual inhibitor of the WEE1 and PLK1 kinases for the treatment of advanced solid and hematological malignancies.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $354621.0 | $4.45m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $561574.0 | $4.41m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $380569.0 | $3.53m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Aprea Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.